All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Fox Chase Cancer Center Welcomes Dr. J. Ryan Mark

July 19th 2024

J. Ryan Mark, MD, FACS, is joining Fox Chase Cancer Center as an associate professor in the Department of Urology and the Fox Chase – Temple Urologic Institute.

EU Approval Sought for Vimseltinib in Tenosynovial Giant Cell Tumor

July 19th 2024

The marketing authorization application seeking the approval of vimseltinib for the treatment of tenosynovial giant cell tumor is under EMA review.

EMA Validates Application for Nivolumab Plus Ipilimumab in Frontline HCC

July 19th 2024

The type II variation application for frontline nivolumab plus ipilimumab in unresectable/advanced hepatocellular carcinoma was validated by the EMA.

EMA Accepts MAA for Belantamab Mafodotin Combos in R/R Multiple Myeloma

July 19th 2024

The EMA has accepted a marketing authorization application seeking approval of belantamab mafodotin regimens in relapsed/refractory multiple myeloma.

Four-Drug Regimens Escalate the SOC for Newly Diagnosed Multiple Myeloma

July 19th 2024

C. Ola Landgren, MD, PhD, highlights how therapeutic improvements with quadruplet regimens will benefit all patients with newly diagnosed multiple myeloma.

Rezatapopt Takes Aim at Previously Untargetable p53 Allele to Treat Advanced Solid Tumors

July 19th 2024

Rezatapopt has displayed early signals of efficacy and tolerability in p53 Y220C-mutated solid tumors.

Exploring Unmet Needs to Optimize Neoadjuvant Therapy in Resectable CRC

July 19th 2024

Richard Kim, MD, discusses the standard treatment approaches and unmet needs for patients with resectable colorectal cancer.

Clear Cell Histology Associated With Increased Risk of irAEs in Metastatic RCC

July 18th 2024

Razane El Hajj Chehade, MD, discusses a retrospective study of risk factors for irAEs in patients with metastatic renal cell carcinoma.

Autologous TIL Therapy Plus Pembrolizumab Under Exploration in PD-L1–Resistant Advanced HNSCC

July 18th 2024

A phase 1b trial is evaluating the TIL therapy TBio-4101 plus pembrolizumab in PD-(L)1 inhibitor–resistant head and neck squamous cell carcinoma.

Quadruplet Regimens Revive Newly Diagnosed Multiple Myeloma Treatment

July 18th 2024

C. Ola Landgren, MD, PhD, discusses the use of quadruplet regimens in patients with newly diagnosed multiple myeloma.

FDA Advises Against Accelerated Approval Pathway for Botensilimab/Balstilimab in R/R MSS CRC

July 18th 2024

The FDA completed an end-of-phase 2 meeting for botensilimab plus balstilimab in relapsed/refractory microsatellite stable colorectal cancer.

NMPA Accepts sNDA for Toripalimab Plus Bevacizumab as Frontline Therapy in Advanced HCC

July 18th 2024

The National Medical Products Administration accepted for review the supplemental new drug application for toripalimab plus bevacizumab in advanced HCC.

Nivolumab/Tivozanib Fails to Improve PFS in Advanced RCC After Prior Immune Checkpoint Inhibition

July 18th 2024

The addition of nivolumab to tivozanib did not improve PFS in advanced metastatic renal cell carcinoma following prior immune checkpoint inhibition

Prostate Cancer Test Is Missing Early Disease in Transgender Women

July 18th 2024

A UCSF-led study alerts transwomen and physicians to interpret standard screening guidelines with caution.

Longest OS Reported From a Third-Line mCRC Randomized Trial Is Seen in ARC-9 Study

July 18th 2024

Tanios S. Bekaii-Saab, MD, highlights data from the phase 1/2 ARC-9 study which showed promising overall survival data in patients with colorectal cancer.

Ibrutinib Plus Venetoclax Generates Durable CRs in TP53+ Mantle Cell Lymphoma

July 18th 2024

Ibrutinib plus venetoclax produced durable complete responses in TP53-mutated mantle cell lymphoma.

Odronextamab Elicits Durable Responses in Heavily Pretreated R/R Follicular Lymphoma

July 17th 2024

Odronextamab elicited deep, durable responses in heavily pretreated patients with relapsed/refractory follicular lymphoma.

Brentuximab Vedotin Triplet Improves Survival Over R2 Across Key R/R DLBCL Subgroups

July 17th 2024

Brentuximab vedotin plus lenalidomide/rituximab (R2) provided a superior overall survival benefit vs R2 alone in relapsed/refractory DLBCL.

Fixed-Duration Venetoclax-Based Combos Maintain Benefit in Frontline CLL

July 17th 2024

Moritz Fürstenau, MD, discusses 4-year follow-up findings from the phase 3 GAIA/CLL13 trial in patients with CLL.

FDA Grants Priority Review to Tabelecleucel for Adult/Pediatric EBV+ Post-Transplant Lymphoproliferative Disease

July 17th 2024

The BLA for tabelecleucel has been granted priority review for the treatment of patients with Epstein-Barr virus–positive post-transplant lymphoproliferative disease.